ganetespib

Small moleculeexperimental

Clinical trial activity

39 trials · 26 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Oct 1, 2007 (NCT00688116)

Timeline

2000s

Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Jan 1, 2009
Earliest Phase 2 Sponsor(trial)

2010s

Jan 1, 2013
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Heat shock protein HSP90INHIBITOR
Heat shock protein HSP90 inhibitor
Resorcinolic triazolone inhibitor of Hsp90. Disrupts the association of HSP90 with its cochaperone, p23.
Binds to the ATP-binding domain at the N-terminus of Hsp90
- Heat shock protein HSP 90-alpha (HSP90AA1) ↗
- Heat shock protein HSP 90-beta (HSP90AB1) ↗
- Heat shock protein HSP 90-alpha
- Heat shock protein HSP 90-beta

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O

Mol. weight: 364.41 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL2103879 ↗

Also known as

ganetespib
ganetespib
ganetespib
ganetespib
ganetespib
sta9090
sta 9090
sta-9090
sta-9090
sta-9090
sta-9090

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03783949	Phase 2	Nov 30, 2018	European Commission, Katholieke Universiteit Leuven
NCT02637375	N/A	May 1, 2016	University of Chicago
NCT02389751	Phase 1	Apr 1, 2015	Synta Pharmaceuticals Corp., University of Texas at Houston
NCT02334319	Phase 1	Dec 1, 2014	Emory University, Synta Pharmaceuticals Corp.
NCT02272478	Phase 3	Oct 1, 2014	Cancer Research UK, Cardiff University, University of Nottingham
NCT02261805	Phase 1/Phase 2 (Phase 2)	Oct 1, 2014	Georgetown University, Synta Pharmaceuticals Corp.
NCT02192541	Phase 1	Jul 9, 2014	National Cancer Institute (NCI)
NCT02012192	Phase 1/Phase 2 (Phase 2)	Jun 1, 2014	European Commission, Medical University Innsbruck
NCT02060253	Phase 1	Apr 1, 2014	Cornell University, National Cancer Institute (NCI), New York University, Synta Pharmaceuticals Corp.
NCT02008877	Phase 1/Phase 2 (Phase 2)	Dec 1, 2013	Children's National Medical Center, Department of Defense, National Cancer Institute (NCI), Sarcoma Alliance for Research through Collaboration, Synta Pharmaceuticals Corp.
NCT01962948	Phase 1/Phase 2 (Phase 2)	Oct 9, 2013	National Cancer Institute (NCI), Temple University
NCT01590160	Phase 1/Phase 2 (Phase 2)	Aug 1, 2013	Cancer Research UK, University of Leicester, University of London
NCT01798485	Phase 3	Apr 1, 2013	Synta Pharmaceuticals Corp.
NCT01677455	Phase 2	Jul 1, 2012	Synta Pharmaceuticals Corp.
NCT01554969	Phase 1	May 1, 2012	Emory University, Synta Pharmaceuticals Corp.
NCT01560416	Phase 2	May 1, 2012	Harvard University
NCT01562015	Phase 2	Apr 1, 2012	Synta Pharmaceuticals Corp.
NCT01579994	Phase 1	Apr 1, 2012	Cornell University
NCT01485835	Phase 1	Jan 1, 2012	Emory University, Multiple Myeloma Research Consortium, Synta Pharmaceuticals Corp.
NCT01551693	Phase 2	Sep 1, 2011	Harvard University, Synta Pharmaceuticals Corp.

Showing 20 of 39 trials

Page 1 / 2

Organizations

Research & Development (26)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Synta Pharmaceuticals Corp.	For profit	25	11	3	2007
Harvard University	Academic/Hospital	7	7	2	2010
National Cancer Institute (NCI)	Government	6	1	2	2010
Cornell University	Academic/Hospital	4	4	2	2010
Emory University	Academic/Hospital	3	3	1	2012
Cancer Research UK	Academic/Hospital	2	0	2	2013
Cardiff University	Academic/Hospital	2	2	2	2011
European Commission	Government	2	0	1	2014
University of Nottingham	Academic/Hospital	2	0	2	2011
Children's National Medical Center	Academic/Hospital	1	0	1	2013
Department of Defense	Government	1	0	1	2013
Georgetown University	Academic/Hospital	1	1	1	2014
Katholieke Universiteit Leuven	Academic/Hospital	1	1	1	2018
Medical University Innsbruck	Academic/Hospital	1	1	1	2014
Multiple Myeloma Research Consortium	Academic/Hospital	1	0	1	2012
New York University	Academic/Hospital	1	0	1	2014
QuantumLeap Healthcare Collaborative	Academic/Hospital	1	1	1	2010
Sarcoma Alliance for Research through Collaboration	Academic/Hospital	1	1	1	2013
Temple University	Academic/Hospital	1	1	1	2013
University of California, San Francisco	Academic/Hospital	1	0	1	2010

26 organizations

Page 1 / 2